MedinCell S.A. Logo

MedinCell S.A.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company that develops a portfolio of long-acting injectable products across various therapeutic areas. The company's core activity involves combining its proprietary BEPO® technology with known active pharmaceutical ingredients to create innovative, extended-release treatments. MedinCell's business model focuses on developing these therapeutic solutions and licensing them to partners for commercialization. The company aims to optimize the efficiency and global accessibility of medical treatments, thereby enhancing and safeguarding patient health worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for MedinCell S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory News Service
Inside Information / Other news releases
English 156.6 KB
2025-05-28 17:45
Regulatory News Service
Inside Information / Other news releases
English 220.0 KB
2025-05-28 17:45
Earnings Release
Informations privilégiées / Autres communiqués
French 218.7 KB
2025-05-21 18:36
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.5 KB
2025-05-07 15:12
Earnings Release
Inside Information / Other news releases
English 227.6 KB
2025-05-07 15:12
Earnings Release
Informations privilégiées / Autres communiqués
French 217.5 KB
2025-04-22 18:11
Regulatory News Service
Informations privilégiées / Autres communiqués
French 194.3 KB
2025-04-22 18:11
Legal Proceedings Report
Inside Information / Other news releases
English 208.5 KB
2025-04-15 19:48
Regulatory News Service
Informations privilégiées / Autres communiqués
French 283.2 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A